Sofosbuvir/Velpatasvir/Voxilaprevir + Rifampin = Prohibited

Effect on Concentration

Sofosbuvir/Velpatasvir/Voxilaprevir
Decrease
Applies within class?
No
Rifampin
No change
Applies within class?
No

Pharmacologic Effects

Sofosbuvir/Velpatasvir/Voxilaprevir
Effect
N/A
Applies within class?
No
Rifampin
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 20-Jul-2018

Summary

Sources

Sofosbuvir/Velpatasvir/Voxilaprevir versus Rifampin ^

Study Design

The Phase 1 program evaluated DDIs between sofosbuvir/velpatasvir/voxilaprevir (S/V/V) and drug transporter and CYP probes, immunosuppressants, HIV antiretrovirals (ARV), and oral contraceptives (OC). S/V/V 400/100/ 100 mg ± VOX 100 mg was administered to healthy volunteers to achieve systemic VOX exposures observed across the HCV-infected patient population, as appropriate.

Study Results

SOF, VEL and VOX AUCwere ↓72%, ↓82% and ↓73% respectively when administered with multiple-dose RIF; use of potent P-gp/CYP inducers with S/V/V is not recommended.

Study Conclusions

The authors concluded that strong PgP/CYP inducers such as rifampin should not be coadminstered with sofosbuvir/velpatasvir/voxilaprevir

References

Garrison KL, Kirby B, Stamm LM, Ma G, Vu A. Drug-drug interaction profile of sofosbuvir/velpatasvir/voxilaprevir fixed-dose combination. Ilc: International Liver Conference. Amsterdam, Netherlands. 2017; April 2017.